Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Management and Treatment of Diabetic Macular Edema after Protocol T

By: Rishi Singh, MD; Mandeep Brar, MD; Mark Dunbar, OD; John Kitchens, MD

This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 1

The release of the 1-year results of the DRCRnet's Protocol T study were of great interest to the retina community. Some physicians saw the data as proof positive that certain disease indicators called for particular therapeutic approaches for DME patients. Others noted that although the data were interesting, 2 years of data were required to fully assess the efficacy of the tested anti-VEGF agents. Now that the 2-year data are released, how should retina specialists apply this new information in the clinic? Join our panel of research experts as they parse the 2-year Protocol T data, enabling you to provide the most effective care for your DME patients.

Expiration Date: Friday, March 31, 2017
Release Date: March 1, 2016

Learning Objectives

Upon completion of this activity, you will be better able to:

  • Assess clinical studies involving new approaches to treat DME, with particular attention to the DRCR.net’s Protocol T
  • Differentiate existing DME intravitreal therapy options from recent primary and secondary treatments
  • Evaluate treatment options and develop criterion/criteria on when to initiate or alter therapy
  • Discuss case scenarios and apply data from recent clinical studies to better manage patients with DME

Accreditation and Designation Statement

Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.

Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Need

The International Diabetes Federation predicts by 2035, more than 590 million people will be living with diabetes (up from the current estimate of 387 million).  Others predict there will be closer to 600 million people with diabetes by 2035. Similarly, the number of people affected by vision-threatening diabetic retinopathy (DR) will rise in tandem.

As newer therapies enter the market, treatment options and dosing strategies can be impacted by the cost of treatment, which continues to be a major factor in treatment planning.   As a result of these newer treatment options, the Diabetic Retinopathy Clinical Research Network (DRCR.net) has undertaken numerous research studies to further define the best treatment options for a variety of patient profiles. (The 2015 PAT survey indicated most retina specialists overwhelmingly (about 60%) would treat a young patient with both anti-VEGF and laser.)

Clinicians using anti-VEGF treatments for DME need to update their knowledge in order to provide their patients with the best understanding of treatment expectations and minimization of risks. It is hoped the results from newly completed and still-ongoing studies from the DRCR.net groups will help achieve those goals.

Faculty and Disclosures

Rishi P. Singh, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speakers Bureau: Alcon, Inc; Genentech, Inc; Regeneron Pharmaceuticals, Inc; and ThromboGenics NV. Contracted Research: Alcon, Inc; Genentech, Inc; Regeneron Pharmaceuticals, Inc.

Mandeep Brar, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speakers Bureau: Janssen Pharmaceutica and Regeneron Pharmaceuticals, Inc.

Mark Dunbar, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speakers Bureau: Allergan, Inc.; Carl Zeiss Meditec and Regeneron Pharmaceuticals, Inc.

John Kitchens, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speakers Bureau: Allergan, Inc.; Genentech, Inc.; Synergetics USA Inc.; and ThromboGenics NV.

Cheryl Cavanaugh, MS; Michelle Dalton; and Melanie Lawler, PhD have no relevant commercial interests to disclose.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC and Regeneron Pharmaceuticals, Inc.

Management and Treatment of Diabetic Macular Edema after Protocol T : WEBINAR

Rishi Singh, MD; Mandeep Brar, MD; Mark Dunbar, OD; John Kitchens, MD

BackNext